Publications by authors named "Michael Shi"

Claim this Profile
A
A xeno-free red blood cell differentiation formula models sickle cell disease from somatically sourced patient iPSCs.
Ashlee J Conway, Tolulope O Rosanwo, Thomas E Williamson, Samuel Landry, Melissa A Kinney, Michael Shi

Exp Hematol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fruquintinib plus sintilimab in patients with advanced endometrial cancer with mismatch-repair proficient status: a multicenter, single-arm, phase Ib/II trial.
Xiaohua Wu, Jing Wang, Danbo Wang, Guiling Li, Jieqing Zhang, Wenyu Shi, Haiyan Shi, Michael Shi

Nat Commun· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corticosteroids in severe alcohol-associated hepatitis. Not so fast: A systematic review of randomized controlled trials.
Michael A Shi, Prisca Pungwe, Lauren L M Comer, Maya Balakrishnan, Tzu-Hao Lee

Hepatology· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of fruquintinib in Chinese patients with colorectal cancer: an age subgroup analysis from a phase IV real-world clinical practice study.
Yi Wang, Yifu He, Zhiqiang Wang, Haijun Zhong, Zuoxing Niu, Michael Shi

Ther Adv Med Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cerebral Edema Leading to Subfalcine and Uncal Herniation in a Patient With Retinal Vasculopathy With Cerebral Leukoencephalopathy and Systemic Manifestations.
Parker Hughes, Liang Lu, Michael Shi, Danial Syed

Neurohospitalist· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ectopic Variceal Bleeding due to Petersen Hernia: A Rare Cause of Recurrent Gastrointestinal Hemorrhage.
Michael A Shi, Conrad J Fernandes, Christy Y Chai, And Ned Snyder Lll

ACG Case Rep J· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HMPL-306 in relapsed or refractory IDH1- and/or IDH2-mutated acute myeloid leukemia: A phase 1 study.
Lijuan Hu, Xudong Wei, Weili Zhao, Yu Hu, Juan Li, Michael Shi

Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surufatinib in advanced neuroendocrine tumours: Final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p).
Jianming Xu, Lin Shen, Jie Li, Zhiwei Zhou, Chunmei Bai, Michael M Shi

Eur J Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic Hepatitis and Hemophagocytic Lymphohistiocytosis Associated With Systemic Chronic Active Epstein-Barr Virus Disease.
Emmanuel Palomera-Tejeda, Lauren Shaffer, Michael Shi, Nagasri Shankar, Roshan Raza

ACG Case Rep J· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sovleplenib in patients with primary or secondary warm autoimmune haemolytic anaemia: results from phase 2 of a randomised, double-blind, placebo-controlled, phase 2/3 study.
Xin Zhao, Jing Sun, Zhihua Zhang, Miao Chen, Tiejun Gong, Michael M Shi

Lancet Haematol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of surufatinib plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer and previously treated small-cell lung cancer: an open-label, single-arm, multicenter, multi-cohort phase II trial.
Ying Cheng, Panpan Zhang, Ming Lu, Zhendong Chen, Lijie Song, Si Shi, Michael Shi

Cancer Immunol Immunother· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fruquintinib Plus Sintilimab in Patients with Treatment-Naive and Previously Treated Advanced Renal Cell Carcinoma: Results from a Phase Ib/II Clinical Trial.
Hua Xu, Xin Yao, Zhisong He, Hong Luo, Guiling Li, Haiyan Shi, Michael Shi

Target Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study.
Yongfeng Yu, Qisen Guo, Yongchang Zhang, Jian Fang, Diansheng Zhong, Michael Shi

Lancet Respir Med· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trial.
Feng Wang, Lin Shen, Weijian Guo, Tianshu Liu, Jin Li, Michael Shi

Nat Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study.
Yu Hu, Xiaofan Liu, Hu Zhou, Shujie Wang, Ruibin Huang, Michael M Shi

Lancet Haematol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer.
Panpan Zhang, Zhendong Chen, Si Shi, Zhiping Li, Feng Ye, Michael Shi

Cancer Immunol Immunother· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial.
Panpan Zhang, Si Shi, Jianming Xu, Zhendong Chen, Lijie Song, Michael Shi

Eur J Cancer· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of MSB2311, a novel pH-dependent anti-PD-L1 monoclonal antibody, treating patients with advanced solid tumors and lymphoma.
Qi Zhang, Jian Zhang, Haijun Zhong, Ying Yuan, Lei Yang, Michael Shi

Cancer Immunol Immunother· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges.
Laura Q M Chow, Fabrice Barlesi, Erin M Bertino, Martin J van den Bent, Heather A Wakelee, Michael Shi

Clin Cancer Res· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Physiological Oxygen on Primary Human Corneal Endothelial Cell Cultures.
Sangita P Patel, Brayan Calle Gonzalez, Nataliia Paone, Christian Mueller, Jamie C Floss, Michael Y Shi

Transl Vis Sci Technol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarker Testing Patterns and Treatment Outcomes in Patients With Advanced Non-Small Cell Lung Cancer and Exon 14 Skipping Mutations: A Descriptive Analysis From the US.
Fatemeh Asad Zadeh Vosta Kolaei, Beilei Cai, Hemanth Kanakamedala, Julia Kim, Vitalii Doban, Shiyu Zhang, Michael Shi

Front Oncol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced -Rearranged NSCLC: An ASCEND-4 Subgroup Analysis.
Daniel S W Tan, Sarayut Geater, Chong-Jen Yu, Chun-Ming Tsai, Te-Chun Hsia, Michael Shi

JTO Clin Res Rep· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
X
Xeno-Free Reprogramming of Peripheral Blood Mononuclear Erythroblasts on Laminin-521.
Christian Skorik, Nathaniel K Mullin, Michael Shi, Yosra Zhang, Phoebe Hunter

Curr Protoc Stem Cell Biol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Morphological and Molecular Defects in Human Three-Dimensional Retinal Organoid Model of X-Linked Juvenile Retinoschisis.
Kang-Chieh Huang, Mong-Lien Wang, Shih-Jen Chen, Jean-Cheng Kuo, Won-Jing Wang, Michael Shi, Shih-Hwa Chiou

Stem Cell Reports· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis.
Abdullah Kutlar, Julie Kanter, Darla K Liles, Ofelia A Alvarez, Rodolfo D Cançado, Michael Shi

Am J Hematol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis